Key result
Mesenchymal stromal cells may protect against diabetic cardiomyopathy, though diabetes impairs their functionality.
Why the study?
Diabetic cardiomyopathy involves multiple pathological features and mesenchymal stromal cells have potential therapeutic effects that need comprehensive summarization.
Do mesenchymal stromal cells improve diabetic cardiomyopathy?
Do mesenchymal stromal cells improve diabetic cardiomyopathy?
This review highlights the potential therapeutic mechanisms of mesenchymal stromal cells in diabetic cardiomyopathy and the challenge of their impaired functionality in the diabetic milieu.
Does not support mesenchymal stromal cell use in diabetic cardiomyopathy yet; leaves open strategies to overcome diabetes-induced impairment.
Diabetic cardiopathy includes a specific cardiomyopathy, which occurs in the absence of coronary heart disease under diabetes mellitus. Hallmarks of diabetic cardiomyopathy are besides others, interstitial inflammation, cardiac oxidative stress, interstitial and perivascular fibrosis, cardiac apoptosis, intramyocardial microangiopathy, endothelial dysfunction, abnormal intracellular Ca²⁺-handling, cardiomyocyte hypertrophy, and impaired cardiac stem cells. Since mesenchymal stromal cells have been shown to have anti-diabetic as well as cardioprotective features, we summarize in this review how they can indirectly affect diabetic cardiomyopathy via their influence on the metabolic trigger hyperglycemia, and how they can directly influence the cardiac cellular consequences typical for diabetic cardiomyopathy via their immunomodulatory, anti-oxidative, anti-fibrotic, anti-apoptotic, pro-angiogenic, and endothelial-protective features, and their ability to activate cardiac progenitor cells. Furthermore, the dysfunctionality of (bone marrow-derived) mesenchymal stromal cells under diabetes mellitus and potential strategies to overcome this impairment in cell functionality are outlined.
No takes yet. Share an insight, caveat, or question.
Linthout et al. (2011) conducted a review in Diabetic cardiomyopathy. Mesenchymal stromal cells was evaluated. Mesenchymal stromal cells may protect against diabetic cardiomyopathy via immunomodulatory, anti-oxidative, and anti-fibrotic mechanisms, though their functionality is impaired by diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: